Business context and reporting period
The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013; this does not match the request metadata naming LifeMD, Inc. Immudyne develops, manufactures, and sells yeast beta-glucan nutraceutical and cosmetic products, focusing on oral and topical products.
Financial performance and liquidity
| Metric | Q1 2013 | Q1 2012 / prior balance-sheet date |
|---|---|---|
| Sales | $230,258 | $178,536 |
| Gross profit / margin | $197,927 / 86% | $148,963 / 83% |
| Operating expenses | $268,444 | $184,789 |
| Operating loss | $(70,787) | $(35,826) |
| Net loss | $(41,487) | $(28,293) |
| Cash from operating activities | $(60,013) | $377 |
| Cash at period end | $38,917 | $98,930 at Dec. 31, 2012 |
| Total liabilities | $244,475 | $234,696 at Dec. 31, 2012 |
Sales increased 29% year over year, attributed to demand for oral and topical products. Cost of sales rose 9%, and gross margin improved to 86%. Operating expenses rose 45%, mainly due to higher compensation, including the new Chief Marketing Officer and product market research, and increased professional fees associated with public-company reporting and an OTCQB uplisting. The net loss widened 46%. Q1 included $25,000 of license-fee income; 2012 included $6,161 of other income from writing off old accounts payable.
At March 31, current assets were $221,534 and current liabilities were $201,175, implying working capital of $20,359. Cash fell by $60,013 during the quarter. The balance sheet reports no note payable; accounts payable and accrued expenses were $201,175, including $110,000 related to royalties. The filing reports an accumulated deficit of approximately $7.8 million and negative operating cash flow, and says these conditions raise substantial doubt about the company’s ability to continue as a going concern. Management expects it will need additional capital for 2013, potentially from increased sales, equity issuance, or debt financing; availability and terms are uncertain.
Outlook, risks, and unusual items
- Management described a 15-month sales and marketing plan and planned new products, but provided no quantified revenue or earnings guidance. It expects marketing and other growth-related costs to increase.
- Customer concentration is significant: one customer represented 77% of Q1 sales and 74% of receivables at March 31, 2013; a second customer represented 11% of sales and 22% of receivables.
- The company relies on additional financing and potentially continued support from officers and directors. Management cautions that future financing may not be available on acceptable terms. Equity financing could dilute shareholders; borrowing could increase debt service and impose covenants.
- An 8% royalty applies to sales of certain skin-care products, subject to a $227,175 cap; approximately $101,000 remained under the commitment. The President has a 60% interest in the royalties and has voluntarily deferred payment without interest.
- Potential risks include intellectual-property protection, government regulation, and product-market execution. Management reported no known material adverse legal proceedings.
- Disclosure controls and procedures were deemed ineffective due to material weaknesses, including inadequate segregation of duties, insufficient written accounting/reporting policies, inadequate computer access and disaster-recovery controls, and no written whistleblower policy. Management described remediation plans subject to funding.
- Potential dilution includes 10.2 million service-based options, 5.4 million performance-based options, and 3.6 million warrants outstanding at quarter end; options and warrants were excluded from diluted loss per share as anti-dilutive.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Immudyne, Inc., not LifeMD, Inc.
- Review cash runway, financing plans, and the going-concern disclosure against subsequent filings and events.
- Assess customer concentration, receivables collectability, and progress toward the stated sales and marketing plan.
- Review royalty accruals, deferred payments to the President, and related-party terms.
- Track remediation of the disclosed control weaknesses and the potential dilution from options and warrants.